Anaphore Takes $25M In Series A

La Jolla-based Anaphore has raised $25M in a Series A financing, the firm said Wednesday, in a funding led by 5AM Ventures, Versant Ventures, and Apposite Capital. The firm, which is developing biopharmaceuticals for treating immune-mediated diseases and oncology, said the funding will go towards developing its protein therapeutics. Anaphore's board is chaired by Andy Schwab of 5AM Ventures, and also includes Brad Bolzon of Verant Ventures, Chris Hollowood of Apposite, Steve Kaldor of Ambrx, and CEo Katherine Bowdish, along with 5AM's Richard Ulevitch. More information »